# Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)

Study · id `cardio:ct-nct02660866` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02660866](<https://clinicaltrials.gov/study/NCT02660866>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02660866

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT02660866. Randomized; quadruple masking; primary purpose treatment. Start 2016-07 (registry gives no type); primary completion 2019-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT02660866, source copy `cardio:ctgov-nct02660866-2018-05-29`, retrieved 2026-10-31)
- Start date: 2016-07 (registry gives no type) (ClinicalTrials.gov record NCT02660866, source copy `cardio:ctgov-nct02660866-2018-05-29`, retrieved 2026-10-31)
- Primary completion: 2019-07 (anticipated) (ClinicalTrials.gov record NCT02660866, source copy `cardio:ctgov-nct02660866-2018-05-29`, retrieved 2026-10-31)
- Completion: 2019-07 (anticipated) (ClinicalTrials.gov record NCT02660866, source copy `cardio:ctgov-nct02660866-2018-05-29`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT02660866, source copy `cardio:ctgov-nct02660866-2018-05-29`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02660866-2018-05-29`, retrieved 2026-10-31)

## The registry's words

- Brief title: Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)
- Acronym: XLPADTRACE
- Condition: Peripheral Arterial Disease
- Intervention (Drug): Placebo + background APT + SMT
- Intervention (Drug): Vorapaxar 2.08 mg/d + background APT + SMT.
- Lead sponsor: North Texas Veterans Healthcare System
- Lead sponsor class: FED

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry lists this organization as the lead sponsor: North Texas Veterans Healthcare System (`cardio:org-north-texas-veterans-healthcare-system`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: No benefit of vorapaxar on walking performance in patients with intermittent claudication (`cardio:pubmed-34609939`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 05a5ac189da127f481fb92c521069e359a53456d2136972f389783e228866638
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
